(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






Health Care Sector

FDA approves drug to treat Parkinson's disease

March 21st, 2017

Silver Spring, MD / CRWE PRESS RELEASE / March 21, 2017 - The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa . Read more

Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody(TM) Therapeutics for the Treatment of Cancer and Other Diseases

March 20th, 2017

* Builds upon initial 2014 alliance in oncology * Includes up to eight additional targets in oncology and other therapeutic areas * CytomX to receive $200 million upfront payment NEW YORK and SOUTH SAN FRANCISCO / CRWE PRESS RELEASE / March 20, . Read more

Hitachi Chemical Signs Agreement to Purchase from Caladrius Biosciences the Remaining 80.1% Interest in PCT for $75 Million

March 16th, 2017

Caladrius expected to emerge as a well-capitalized cell therapeutics-only development company with multiple proprietary technology platforms Conference call begins tomorrow, March 17, 2017 at 8:30 am Eastern time BASKING RIDGE, N.J. / CRWE PRES. Read more

Kitov Announces License Agreement for KIT-302 in South Korea

March 08th, 2017

Definitive agreement grants Kuhnil Pharmaceutical Co. Ltd. an exclusive license to manufacture and market KIT-302 in South Korea Transaction is Kitov's First License Agreement for KIT-302 Celecoxib is the leading NSAID product in South Kore. Read more

ASPiRA LABs Announces Provider Status with Medi-Cal Expanding OVA1(R) Access to Over 12 Million Beneficiaries

March 06th, 2017

AUSTIN, Texas / CRWE PRESS RELEASE / March 6, 2017 — ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced it has attained out-of-state provider status with Medi-Cal, California’s Medicaid program, for OVA1®/Multivari. Read more

Diplomat to Dispense XERMELO(TM) for Patients With Carcinoid Syndrome Diarrhea

March 06th, 2017

FLINT, Mich. / CRWE PRESS RELEASE / March 6, 2017 – The nation’s largest independent specialty pharmacy has been selected to the limited-distribution panel of XERMELO™ (telotristat ethyl). Diplomat Pharmacy, Inc. (NYSE: DPLO), wi. Read more

ASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1(R)

March 01st, 2017

AUSTIN, Texas / CRWE PRESS RELEASE / March 1, 2017 — ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced a major contracted agreement with Blue Cross Blue Shield of Michigan for ASPiRA’s U.S. FDA cleared, American Colle. Read more

Ballard Inks $25M Deal With Broad-Ocean For Fuel Cell Engine Manufacture & Sales in China

February 16th, 2017

VANCOUVER, CANADA and ZHONGSHAN, CHINA / CRWE PRESS RELEASE / February 16, 2017 - Ballard Power Systems (NASDAQ: BLDP; TSX: BLDP) today announced that it has signed a definitive agreement relating to technology transfer, licensing and supply arr. Read more

Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook

February 13th, 2017

HAIFA, Israel / CRWE PRESS RELEASE / February 13, 2017 - Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PSTI), a leading developer of placenta-based cell therapy products, today reported financial update and corporate and clinical developments for . Read more

Kitov Provides Further Update on Formal Investigation by Israeli Securities Authority

February 09th, 2017

Tel Aviv, Israel / CRWE PRESS RELEASE / February 9, 2017 - Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, in response to requests made by the NASDAQ Stock Market, today provided a further upda. Read more

EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects

January 30th, 2017

Company Plans to Continue Development with Next Controlled Trial Q2 2017 WALTHAM, Mass. / CRWE PRESS RELEASE / January 30, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharma. Read more

Load More Content